WO2011132943A3 - Composition for treatment of acute pseudomembranous colitis - Google Patents

Composition for treatment of acute pseudomembranous colitis Download PDF

Info

Publication number
WO2011132943A3
WO2011132943A3 PCT/KR2011/002845 KR2011002845W WO2011132943A3 WO 2011132943 A3 WO2011132943 A3 WO 2011132943A3 KR 2011002845 W KR2011002845 W KR 2011002845W WO 2011132943 A3 WO2011132943 A3 WO 2011132943A3
Authority
WO
WIPO (PCT)
Prior art keywords
bacteria
treatment
composition
copa3
pseudomembranous colitis
Prior art date
Application number
PCT/KR2011/002845
Other languages
French (fr)
Other versions
WO2011132943A9 (en
WO2011132943A2 (en
Inventor
Jae Sam Hwang
Eun Yeong Yun
Seong Ryeol Kim
Seong Hui Nam
Mi Yeong Ahn
Yeong Cheol Choi
Ho Kim
Hyo Jung Nam
Jin Ku Kang
In Woo Kim
Original Assignee
Republic Of Korea(Management : Rural Development Administration)
Daejin University Center For Educational Industrial Cooperation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Republic Of Korea(Management : Rural Development Administration), Daejin University Center For Educational Industrial Cooperation filed Critical Republic Of Korea(Management : Rural Development Administration)
Publication of WO2011132943A2 publication Critical patent/WO2011132943A2/en
Publication of WO2011132943A3 publication Critical patent/WO2011132943A3/en
Publication of WO2011132943A9 publication Critical patent/WO2011132943A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Disclosed is a composition for treatment of pseudomembranous colitis including a coprisin peptide derivative CopA3 (HL) having the following amino acid sequence, as an active ingredient: L-L-C-A-L-R-K-K. According to the present disclosure, the coprisin peptide derivative CopA3 (HL) does not show antibiotic effects upon effective colon microorganisms such as Bifidobacterium, Lactobacillus, or the like, while having antibiotic effects specific to Cd bacteria as a pathogenic microorganism. Effects of CopA3 (HL) for inhibiting growth of Cd bacteria have been verified through animal testing, and Cd bacteria-derived intestinal inflammation and villous necrosis processes are effectively relieved.
PCT/KR2011/002845 2010-04-22 2011-04-20 Composition for treatment of acute pseudomembranous colitis WO2011132943A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2010-0037204 2010-04-22
KR1020100037204A KR101021226B1 (en) 2010-04-22 2010-04-22 Therapeutic usage of copa3 peptide analogue isolated from copris tripartitus for c. difficile-pseudomembranous colitis and general gut inflammation

Publications (3)

Publication Number Publication Date
WO2011132943A2 WO2011132943A2 (en) 2011-10-27
WO2011132943A3 true WO2011132943A3 (en) 2012-03-08
WO2011132943A9 WO2011132943A9 (en) 2012-04-05

Family

ID=43938730

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/002845 WO2011132943A2 (en) 2010-04-22 2011-04-20 Composition for treatment of acute pseudomembranous colitis

Country Status (2)

Country Link
KR (1) KR101021226B1 (en)
WO (1) WO2011132943A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101336023B1 (en) 2011-11-23 2013-12-03 대진대학교 산학협력단 A Composition For Controlling the Growth of Nerve Cells
KR101633158B1 (en) * 2013-11-28 2016-06-23 부경대학교 산학협력단 Composition for treating or preventing intestinal disorders comprsing peptide derived from chlamidomonas sp.
KR102177839B1 (en) * 2016-07-29 2020-11-12 대진대학교 산학협력단 Composition for treating chronic inflammatory bowel diseases or for improving bowel function
KR101980253B1 (en) 2017-04-24 2019-05-21 대한민국(농촌진흥청장) Composition comprising peptide Periplanetasin-4 isolated from Periplaneta americana for preventing or treating pseudomembranous colitis
KR102549795B1 (en) * 2020-10-20 2023-06-30 대한민국(농촌진흥청장) Composition for preventing or treating of alcoholic liver disease comprising coprisin peptide CopA derived from Copris tripartitus

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GIESEMANN, T. ET AL.: "Human a-Defensins Inhibit Clostridium difficile Toxin B.", GASTROENTEROLOGY., vol. 134, no. 7, 2008, pages 2049 - 2058 *
HWANG, J. ET AL.: "Isolation and Characterization of a Defensin-Like Peptide (Coprisin) from the Dung Beetle, Copris tripartitus.", INTERNATIONAL JOURNAL OF PEPTIDES., vol. 2009, no. 136284, 2009, pages 1 - 5 *

Also Published As

Publication number Publication date
WO2011132943A9 (en) 2012-04-05
WO2011132943A2 (en) 2011-10-27
KR101021226B1 (en) 2011-03-11

Similar Documents

Publication Publication Date Title
Sokovic Bajic et al. GABA-producing natural dairy isolate from artisanal zlatar cheese attenuates gut inflammation and strengthens gut epithelial barrier in vitro
MX339951B (en) Bacillus subtilis isolate from corn.
Ouali et al. Identification of lactobacilli with inhibitory effect on biofilm formation by pathogenic bacteria on stainless steel surfaces
WO2011132943A3 (en) Composition for treatment of acute pseudomembranous colitis
EP3479824A3 (en) Peptides and their use
PH12015502416A1 (en) Bacterial strains having antimicrobial activity and biocontrol compositions comprising the same
MY172363A (en) Lipid metabolism and/or sugar metabolism improver containing lactic acid bacterium or treatment product thereof
WO2012003474A3 (en) Compositions and methods related to protein a (spa) variants
Valledor et al. Characterization and safety evaluation of two beneficial, enterocin-producing Enterococcus faecium strains isolated from kimchi, a Korean fermented cabbage
WO2018208987A3 (en) Antibacterial compounds
NZ591051A (en) C7-fluoro substituted tetracycline compounds
WO2014066053A3 (en) Method of prevention and treatment of clostridium difficile infection
WO2018231992A3 (en) Methods of using lactobacillus plantarum strains for protecting animals from pathogenic bacterial infection
WO2009102143A3 (en) Kimchi-based lactobacillus plantarum bls41 and use thereof
NZ594019A (en) Novel antibacterial agents for the treatment of gram positive infections
US10201574B1 (en) Methods of microbial treatment of poultry
Mahdhi et al. Preliminary characterization of the probiotic properties of Candida famata and Geobacillus thermoleovorans
IN2012DN02283A (en)
WO2013041663A3 (en) Modified apidaecin derivatives as antibiotic peptides
Jitpakdee et al. Potential of lactic acid bacteria to produce functional fermented whey beverage with putative health promoting attributes
Sarmurzina et al. Characterization of probiotic strains of Lactobacillus candidates for development of synbiotic product for Kazakh population.
MX2017007969A (en) Lactic acid bacteria and their use for the treatment of mastitis.
MX2009006808A (en) Growth inhibition and elimination of methicillin-resistant staphylococcus aureus by lactic acid bacteria.
RU2007146645A (en) BACTERIAL PREPARATION FOR THE PRODUCTION OF FERMENTED MEAT PRODUCTS AND BIO-TRANSFORMATION OF MEAT RAW MATERIALS
WO2020237009A8 (en) Methods and compositions for anaerobic bacterial fermentation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11772231

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11772231

Country of ref document: EP

Kind code of ref document: A2